Novavax’s plans for growth outside of COVID have been thrown into chaos after the FDA put the biopharma's flu programs on hold. The regulatory hold is in response to a case of nerve disease in a former trial participant who received the biotech’s COVID-flu combo shot.
Fierce Biotech
信息服务
New York，New York 92,816 位关注者
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
关于我们
Fierce Biotech is the dominant B2B news brand for the industry. Our focus daily is on biotech and medtech companies. We cover the drug and device development universe as well as the financing, deals, IPOs and M&A that happen along the way and the people who move biotech and medtech forward. Our coverage also feeds longer-form content, podcasts and events. Our journalists track the news closely and have developed a network of contacts to bring you exclusives. Our coverage runs the gamut from good news to bad and flattering to unflattering to give readers and listeners an unvarnished view of what’s truly happening. Delivering news, revealing insights straight to your inboxes: https://fiercebiotech.questexinfo.com/loading.do?omedasite=LS_full. Our family of publications includes Fierce Biotech, Fierce Biotech PM Tracker, Fierce Medtech, Fierce Biotech Research, Fierce CRO, Fierce Life Sciences Weekly Digest and Fierce Cell & Gene Therapy. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Pharma news you can’t miss: https://www.dhirubhai.net/company/fierce-pharma For Healthcare news you can’t miss: https://www.dhirubhai.net/showcase/fierce-healthcare
- 网站
-
https://www.fiercebiotech.com/
Fierce Biotech的外部链接
- 所属行业
- 信息服务
- 规模
- 51-200 人
- 总部
- New York，New York
- 创立
- 2001
动态
-
Johnson & Johnson has?burnished?the evidence for nipocalimab, adding a sliver of data in adolescents with generalized myasthenia gravis to the growing case for its near-approval FcRn blocker.
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
fiercebiotech.com
-
After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is?scooping up the biotech?for $2.5 billion.
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
fiercebiotech.com
-
Difficult. Impossible. Agonizing. Worse than voting in the national election. All those descriptors were used today by FDA advisory committee members when asked to vote on an investigational rare disease therapy.?
'Impossible' FDA adcomm ends in favor of Stealth’s ultra-rare disease med
fiercebiotech.com
-
Upstream Bio has upsized its IPO to $255 million as the company joins CAMP4 Therapeutics this morning as the latest biotechs to list on the Nasdaq.
Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
fiercebiotech.com
-
In another blow to its $525 million ReViral buy, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat RSV.
'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout
fiercebiotech.com
-
The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J?halted the phase 3 bladder cancer trial after an interim look at the data showed the TAR-200 candidate was no better than chemoradiation.
J&J stops phase 3 trial of $5B bladder cancer prospect after interim review flop
fiercebiotech.com
-
As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with quarterly layoffs evening out to similar levels as the same time last year.
This year's biopharma layoff rate on track with 2023: Fierce Biotech Q3 analysis
fiercebiotech.com
-
The Nobel Assembly?at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists the 2024 Nobel Prize in Physiology or Medicine for their discovery of microRNA a year after the prize went to scientists who conducted?foundational work on mRNA vaccines.
Nobel Prize in Physiology or Medicine awarded to 2 discoverers of microRNA
fiercebiotech.com
-
The U.S. Department of Veterans Affairs (VA) provides life-changing healthcare for our nation's veterans. But, the VA needs U.S. businesses to bring the next groundbreaking innovation to market. TechLink, the VA's official technology transfer partner, connects businesses with VA inventors to license and commercialize novel technology and treatments. ?? https://loom.ly/veJHZVk Interested in partnering with the VA to accelerate research and development of new healthcare products? Explore the VA's history of innovation to see where your business aligns for the future. ?? https://loom.ly/veJHZVk #Sponsored
-